⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321509 | 1.00 | — | — | |
| SCHEMBL492237 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL331264 | 0.97 | — | — | |
| Bromide SCHEMBL6581171 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL22117616 | 0.97 | — | — | |
| Bromide SCHEMBL6581168 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL331433 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL492735 | 0.97 | — | — | |
| SCHEMBL118935 | 0.84 | — | — | |
| SCHEMBL4467686 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 717 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | claimed |
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-08-25 | — | — | US | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260109697-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2026-04-23 | — | — | US | disclosed |
| EP-4709723-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709714-A1 | SUBSTITUTED QUINOXALINES | Mirati Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705300-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| EP-4430042-B1 | 6-HETERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | disclosed |
| US-5362738-A | Used to treat muscle tension, stress, insomnia, anxiety or convulsions | HOFFMANN-LA ROCHE INC. (US) | 1994-11-08 | — | — | US | disclosed |
| US-5258387-A | Controlling muscle tension, stress, insomnia, anxiety or convulsions | HOFFMANN-LA ROCHE INC. (US) | 1993-11-02 | — | — | US | disclosed |
| US-5143912-A | Muscle relaxants, anticonvulsants, anxiolytic agents | HOFFMANN-LA ROCHE, INC. (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0472166-A1 | Tricyclic pyridone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-02-26 | — | — | EP | disclosed |
| US-5082842-A | Sedatives | HOFFMANN-LA ROCHE INC. (US) | 1992-01-21 | — | — | US | disclosed |
| US-4889854-A | MUSCLE RELAXANT, SEDATIVE-HYPNOTIC, ANXIOLYTIC AND-OR ANTICONVULSANT ACTIVITY | HOFFMAN-LA ROCHE INC. (US) | 1989-12-26 | — | — | US | disclosed |
| EP-0294599-A2 | Tricyclic pyridone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-12-14 | — | — | EP | disclosed |